{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Sun G"],"pubmed_abstract":["<h4>Background</h4>Emerging evidence indicates a link between gut dysbiosis and allergic rhinitis (AR) pathogenesis. Nevertheless, the mechanistic role of gut microbiota in AR progression requires further characterization. To address this, we employed an integrated multi-omics strategy to delineate gut microbial composition and metabolic signatures in AR patients.<h4>Methods</h4>Fecal specimens from 23 AR patients and 15 matched healthy controls (total <i>n</i> = 38) were subjected to 16S rRNA gene sequencing to assess bacterial community structure, alongside untargeted metabolomic profiling of microbial metabolites. Spearman's rank correlation analysis was applied to evaluate microbiota-metabolite interactions.<h4>Results</h4>Allergic rhinitis patients exhibited altered gut microbial community structure (beta diversity, <i>P</i> < 0.05) with depletion of SCFA-producing genera such as <i>Faecalibacterium</i> and enrichment of pro-inflammatory taxa like <i>Fusobacterium</i>. Metabolomic profiling identified significant disturbances in pathways including pantothenate and CoA biosynthesis, glycolysis, and pyruvate metabolism. Key discriminatory metabolites included maltol and 4-coumaric acid. Integrative analysis revealed significant correlations between specific bacteria and metabolites, such as <i>Faecalibacterium</i> with D-phenyllactic acid (ρ = 0.515, <i>q</i> = 0.046).<h4>Conclusion</h4>Our findings demonstrate that AR is associated with gut dysbiosis and metabolic dysfunction, highlighting the role of microbial-derived metabolites in immune regulation via the gut-nose axis. These insights support the potential for microbiota-targeted therapeutic strategies in AR management."],"journal":["Frontiers in microbiology"],"pagination":["1652915"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12646992"],"repository":["biostudies-literature"],"pubmed_title":["Integrated gut microbiome and metabolomics analysis reveals microbial-metabolic cross-talk in allergic rhinitis."],"pmcid":["PMC12646992"],"pubmed_authors":["Zhao S","Guan W","Chai R","Huang H","Zhang H","Hou D","Xu C","Zhang M","Sun G","Wang X"],"additional_accession":[]},"is_claimable":false,"name":"Integrated gut microbiome and metabolomics analysis reveals microbial-metabolic cross-talk in allergic rhinitis.","description":"<h4>Background</h4>Emerging evidence indicates a link between gut dysbiosis and allergic rhinitis (AR) pathogenesis. Nevertheless, the mechanistic role of gut microbiota in AR progression requires further characterization. To address this, we employed an integrated multi-omics strategy to delineate gut microbial composition and metabolic signatures in AR patients.<h4>Methods</h4>Fecal specimens from 23 AR patients and 15 matched healthy controls (total <i>n</i> = 38) were subjected to 16S rRNA gene sequencing to assess bacterial community structure, alongside untargeted metabolomic profiling of microbial metabolites. Spearman's rank correlation analysis was applied to evaluate microbiota-metabolite interactions.<h4>Results</h4>Allergic rhinitis patients exhibited altered gut microbial community structure (beta diversity, <i>P</i> < 0.05) with depletion of SCFA-producing genera such as <i>Faecalibacterium</i> and enrichment of pro-inflammatory taxa like <i>Fusobacterium</i>. Metabolomic profiling identified significant disturbances in pathways including pantothenate and CoA biosynthesis, glycolysis, and pyruvate metabolism. Key discriminatory metabolites included maltol and 4-coumaric acid. Integrative analysis revealed significant correlations between specific bacteria and metabolites, such as <i>Faecalibacterium</i> with D-phenyllactic acid (ρ = 0.515, <i>q</i> = 0.046).<h4>Conclusion</h4>Our findings demonstrate that AR is associated with gut dysbiosis and metabolic dysfunction, highlighting the role of microbial-derived metabolites in immune regulation via the gut-nose axis. These insights support the potential for microbiota-targeted therapeutic strategies in AR management.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-05T16:49:55.863Z","creation":"2026-05-19T03:11:47.333Z"},"accession":"S-EPMC12646992","cross_references":{"pubmed":["41311502"],"doi":["10.3389/fmicb.2025.1652915"]}}